Evaluate Purchases J+D Forecasting
Acquisition is expected to offer life sciences clients a boost in expertise and insight.
Evaluate, who is not only a Norstella company, but also a consulting and forecasting source of data and insight for the life sciences sector, has acquired J+D Forecasting, a provider of forecasting solutions for the pharmaceutical industry.
The company noted that global pharma industry is undergoing a period of change and uncertainty, due in part to changes in legislation and regulation, the current geopolitical environment, and patent expiration. Therefore, the ability to accurately determine forecast market size, spot growth trends in various categories, and keep up with new technology have become more of a necessity. The combination of Evaluate’s consensus forecasting and consulting knowledge with J+D Forecasting’s specialized models that are delivered via cloud-based management and analytical solutions are expected to assist clients with creating more intelligent and consistent insights, while having the parties combined collaborate throughout the entire process.
“We are delighted to welcome the J+D Forecasting team to the Norstella family. Their expertise in developing bespoke forecasting models and innovative, intuitive solutions will provide our customers with an even wider breadth of expertise and cutting-edge insight,” said Mike Gallup, CEO, Norstella’s CEO. “The addition of these capabilities significantly boosts our ability to help achieve our mission of smoothing the path of life-saving therapies from pipeline to patient.”
Norstella will continue its efforts in expanding its forecasting portfolio by incorporating J+D Forecasting's models and employing GenAI to synthesize insights from various models, with the goal of designing a “one-stop solution” for all forecasting necessities.
“The need for high-quality forecasting to support decision making in the pharmaceutical and biotech space has never been higher …. I am looking forward to working with the Evaluate team and Norstella to bring innovative solutions to the market,” commented David James, founder and CEO, J+D Forecasting.
Reference
Evaluate, a Norstella company, announces acquisition of J+D Forecasting. GlobeNewswire. January 10, 2024. Accessed January 10, 2024. https://www.globenewswire.com/news-release/2024/01/10/2807051/0/en/Evaluate-a-Norstella-company-announces-acquisition-of-J-D-Forecasting.html
An Exploration of Compounding Practices
May 22nd 2025In a Q&A with Pharma Commerce, Kurt Lunkwitz, ProRx Pharma’s COO, uncovers the stringent requirements that 503B outsourcing facilities must abide by under the Drug Quality and Security Act, while also shedding light on the FDA’s impact when it comes to improving the safety, quality, and trust in compounded drugs.
